Bones & muscles GHRP / ghrelin receptor agonist
Ipamorelin
Regulatory status
Status at a glance
503A compounding status
Removed from Category 2 (review pending)
FDA has moved this substance out of Category 2 while it is reviewed further. Removal from Category 2 does not authorize compounding. Its status remains unsettled until FDA completes its evaluation.
- FDA approval
- Not FDA-approved for any use
- 503B outsourcing
- Excluded
- Anti-doping (WADA)
- On the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Ipamorelin is a synthetic peptide that mimics ghrelin to prompt the body to release more of its own growth hormone, and it is sold on the wellness and "research peptide" market. In a phase 2 trial of 114 bowel-resection patients (Beck, 2014), intravenous ipamorelin brought a median first tolerated meal at 25.3 hours versus 32.6 hours on placebo, a difference that was not significant (p = 0.15). Other human data show only that it raises growth hormone. As of 2026 it is not FDA-approved, it is not eligible for routine pharmacy compounding, and it is banned in sport.
At a glance
- FDA status
- Non-FDA-approved peptide sold in the wellness/gray market
- What it is
- Selective ghrelin-receptor agonist ("growth hormone secretagogue")
- Research
- Human data are limited to short pharmacology studies; benefit for recovery or body composition is unproven
- Sport
- Prohibited by WADA at all times
- Evidence strength
- Low research
Summary
Ipamorelin is a ghrelin-mimicking peptide that raises growth hormone. Human data are limited to short studies, it is not FDA-approved, and sport bans it.
What is ipamorelin?
Ipamorelin is an experimental five-amino acid peptide that acts as a ghrelin mimic, developed years ago under the code NNC 26-0161 but never marketed as a drug. It is sold through wellness and "research peptide" channels and promoted for recovery, body composition, and sleep, often paired with a GHRH analog such as CJC-1295 or sermorelin.
How does it work?
Ipamorelin activates the growth hormone secretagogue receptor, the same receptor the hunger hormone ghrelin uses, which triggers the pituitary to release growth hormone in pulses. In laboratory work it is described as relatively "selective," raising growth hormone with comparatively little effect on other hormones such as cortisol and prolactin. In conscious swine, it released GH without raising ACTH or cortisol, while GHRP-6 and GHRP-2 raised both.
Because growth hormone and GHRH signaling act together, ghrelin-mimic peptides are often combined with GHRH analogs. No published human randomized controlled trial tests ipamorelin with CJC-1295 as of September 2026. The marketed benefits are extrapolated from this growth-hormone effect. This describes the proposed mechanism, separate from proven outcomes.
Is it FDA-approved?
Safety note
Status: Non-FDA-approved peptide sold in the wellness/gray market
Category: Wellness and performance · Primary body area: Bones & muscles
No. Ipamorelin is not approved by the FDA and never reached market as a drug. Its compounding and sport status:
- Not eligible for routine 503A compounding, because its 503A nomination was withdrawn
- Still on FDA's 503B Category 2 list
- Prohibited at all times in sport under the WADA list, which covers growth hormone secretagogues including ipamorelin
What does the research show?
Editor’s note
Evidence strength: Low research (2 human · 2 animal/cell studies)
Human data are limited to short studies of growth hormone release and one phase 2 ileus trial that missed its endpoint, and the marketed recovery and body-composition claims rest on animal and laboratory work.
The human evidence is short pharmacology, not outcomes, and the supporting bone and gut data come from animal models:
| Study | Subjects | Finding |
|---|---|---|
| Dose-ranging study, according to PubMed | Healthy men | Ipamorelin induced growth hormone release, a hormone-level finding rather than a clinical result; the study estimated a terminal half-life of 2 hours |
| Bone study | Rats with glucocorticoid-related bone changes | Supporting data on bone effects |
| Gut transit model | Rodent model of post-operative gut transit | Supporting data on gut effects |
| The one published phase 2 efficacy trial (Beck, 2014) | 114 patients analyzed, adults after bowel resection, given intravenous ipamorelin or placebo | Median time to first tolerated meal was 25.3 versus 32.6 hours, p = 0.15, so it missed its primary endpoint; its secondary efficacy analyses showed no significant differences either |
Clinical development for post-operative ileus did not produce an approved product, and there are no controlled human trials supporting the marketed recovery or body-composition uses.
Sources: a pharmacodynamic study of ipamorelin (Gobburu et al., Pharmaceutical Research, 1999, DOI: 10.1023/a:1018955126402); animal studies on bone (Andersen et al., Growth Hormone & IGF Research, 2001, DOI: 10.1054/ghir.2001.0239) and gut transit (Venkova et al., Journal of Pharmacology and Experimental Therapeutics, 2009, DOI: 10.1124/jpet.108.149211), all indexed on PubMed; and the WADA Prohibited List. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.
Registered human trials
2 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
Compare every peptide’s status in the peptide regulatory status database
More for Bones & muscles
View all bones & muscles peptides →- FDA-approved Bones & muscles
Abaloparatide
Abaloparatide is a synthetic 34-amino acid analog of parathyroid hormone-related protein (PTHrP) that activates the PTH1 receptor to stimulate new bone formation. FDA-approved in 2017 as Tymlos, it is a daily injection for postmenopausal women and men with osteoporosis at high fracture risk, and it is capped at two years of use. In the pivotal ACTIVE trial, it cut the risk of new spine fractures by about 86% versus placebo.
- FDA-approved Bones & muscles
Calcitonin-Salmon
Miacalcin (injection), nasal spray sold as a generic
Calcitonin-salmon is an FDA-approved synthetic version of a natural hormone that slows bone breakdown, used mainly for postmenopausal osteoporosis, Paget's disease of bone, and high blood calcium (hypercalcemia). It comes as an injection, sold as Miacalcin, and as a nasal spray sold as a generic. A modest effect on fractures and a small possible cancer risk with long-term use make it a second-line option today.
- Not FDA-approved Bones & muscles
Cjc-1295
CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone (GHRH). In two placebo-controlled trials of healthy adults aged 21 to 61 (Teichman, 2006), a single injection raised mean growth hormone 2- to 10-fold for 6 days or more. Mean IGF-1 rose 1.5- to 3-fold, but no controlled human trial shows benefit for muscle, fat loss, recovery, or anti-aging. CJC-1295 is not FDA-approved, it is not eligible for routine pharmacy compounding, and it is banned in sport.
- FDA-approved Bones & muscles
Etelcalcetide
Etelcalcetide (sold as Parsabiv) is a peptide that activates the calcium-sensing receptor to lower parathyroid hormone, used for secondary hyperparathyroidism in people on dialysis for kidney disease. Unlike parathyroid hormone replacement, it suppresses an overactive parathyroid signal, and it is given intravenously at the end of each dialysis session. It has been FDA-approved in the U.S. since 2017.
- Not FDA-approved Bones & muscles
Follistatin-344
Follistatin-344 is a form of the natural protein follistatin that blocks myostatin, a brake on muscle growth, sold as a "research chemical" in the performance market for muscle gain. The strongest human data come from gene therapy, not the injectable peptide. In a small 2017 trial, six patients with sporadic inclusion body myositis gained a median 56.0 m per year on the 6-minute walk test after follistatin gene therapy, versus a 25.8 m decline in eight matched untreated controls (p = 0.01). It is not FDA-approved and is banned in sport.
- Not FDA-approved Bones & muscles
Ghrp-2
Pralmorelin
GHRP-2 (pralmorelin) is a synthetic ghrelin-mimic peptide that prompts the pituitary to release growth hormone, sold in the wellness market for muscle, recovery, and appetite. Its only genuine validated use is as a diagnostic test of growth hormone capacity (approved in Japan), not as a treatment, and there are no controlled trials supporting the marketed wellness benefits. As of 2026 it is not FDA-approved and is banned in sport.